Ailton Melo

Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers

BackgroundA small fraction of Human T cell Leukemia Virus type-1 (HTLV-I) infected subjects develop a severe form of myelopathy. It has been established that patients with HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) show an exaggerated immune response when compared with the immunological response observed in HTLV-I asymptomatic carriers. In this study the immunological responses in HAM/TSP patients and in HTLV-I asymptomatic carriers were compared using several immunological assays to identify immunological markers associated with progression from infection to disease.MethodsImmunoproliferation assays, cytokine levels of unstimulated cultures, and flow cytometry analysis were used to evaluate the studied groups. Nonparametric tests (Mann-Whitney U test and Wilcoxon matched-pairs signed ranks) were used to compare the difference between the groups.ResultsAlthough both groups showed great variability, HAM/TSP patients had higher spontaneous lymphoproliferation as well as higher IFN-γ levels in unstimulated supernatants when compared with asymptomatic carriers. Flow cytometry studies demonstrated a high frequency of inflammatory cytokine (IFN-γ and TNF-α) producing lymphocytes in HAM/TSP as compared to the asymptomatic group. This difference was accounted for mainly by an increase in CD8 cell production of these cytokines. Moreover, the HAM/TSP patients also expressed an increased frequency of CD28-/CD8+ T cells. Since forty percent of the asymptomatic carriers had spontaneous lymphoproliferation and IFN-γ production similar to HAM/TSP patients, IFN-γ levels were measured eight months after the first evaluation in some of these patients to observe if this was a transient or a persistent situation. No significant difference was observed between the means of IFN-γ levels in the first and second evaluation.ConclusionsThe finding that a large proportion of HTLV-I carriers present similar immunological responses to those observed in HAM/TSP, strongly argues for further studies to evaluate these parameters as markers of HAM/TSP progression.

Interferon-γ and Interleukin-4 Responses in Relation to Serum IgE Levels in Persons Infected with Human T Lymphotropic Virus Type I and Strongyloides stercoralis

Possible immunologic interaction between infection with human T lymphotropic virus type 1 (HTLV-1), a retrovirus, and the intestinal parasite Strongyloides stercoralis was investigated in persons infected with one or both agents. This was done by examining the cytokine responses of peripheral blood mononuclear cells (PBMC) to mitogens and Strongyloides antigen. PBMC of subjects infected with HTLV-1 spontaneously produced interferon (IFN)-gamma with levels that correlated inversely with serum IgE levels. HTLV-1-infected subjects also had poor interleukin (IL)-4 responses to mitogenic stimulation, unlike persons without HTLV-1 infection. It is postulated that the IFN-gamma produced by activated T cells in some HTLV-1-infected persons acts to down-regulate IL-4 with consequent reduction of serum IgE levels. The impaired IgE responses and other effects of IL-4 down-regulation may be contributing factors to more severe disease and impaired response to treatment of strongyloidiasis in some HTLV-1-infected persons.

Does levodopa improve swallowing dysfunction in Parkinson’s disease patients?

Objective:  To assess the influence of levodopa on swallowing dysfunction in Parkinson’s disease patients.

Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine

OBJECTIVE To compare the effects of botulinum toxin type A with those of amitriptyline on the treatment of chronic daily migraines. METHODS Chronic migraine sufferers were randomized into two groups and treated with 25 or 50mg/day of amitriptyline or 250U of botulinum toxin type A. A reduction of at least 50% in the number of pain episodes, in the intensity of pain, and in the number of drug doses for pain and reports of improvement by the patient or by the examiner were the main endpoints. RESULTS Seventy-two subjects were enrolled in the study. A reduction of at least 50% in the number of days of pain was recorded in 67.8% of the patients in the BTX-A group and 72% (n=23) of the patients in the AM group (p=0.78; RR=0.94; CI=0.11-8). The reduction in the intensity of pain, as assessed using the visual analogical scale, was 50% in the BXT-A group and 55.6% in the AM group (p=0.79; RR=1.11; CI=0.32-3.8). The reduction in the number of pain drug doses was 77% for the toxin group and 71% for the amitriptyline group (p=0.76; RR=0.92; CI=0.45-1.88). CONCLUSIONS Botulinum toxin type A was as effective as amitriptyline for the prophylactic treatment of chronic daily migraines.

Silent saliva aspiration in Parkinson's disease

Background: Silent laryngeal penetration and silent aspiration (SLP/SA) are common manifestations in Parkinsons disease (PD) patients and are frequently associated with dysphagia. However, little is known about saliva aspiration in this population. Objective: We investigated the frequency and characteristics of saliva SLP/SA in PD patients with daily drooling (Group A) and in individuals without PD or daily drooling (Group B). Method: Both groups were evaluated by fiberoptic endoscopic evaluation of swallowing (FEES) after dyeing the oral cavity with blue dye. The oropharynx was assessed for the presence of the stasis of saliva, and sensitivity was tested by direct tactile stimuli. Results: PD patients (n = 28) and controls (n = 18) were evaluated. We observed silent aspiration of saliva in 10.7% and silent laryngeal penetration of saliva near the vocal folds in 28.6% of Group A; however, none of these events was observed in Group B. Sensitivity in the epiglottis and posterior wall of the hypopharynx was decreased in 89.2% of Group A and in 33.3% of Group B, whereas in the aryepiglottic folds and interarytenoid area, a decrease in sensitivity was observed in 92.8% and in 44.4% of Groups A and B, respectively. Conclusion: Silent aspiration and laryngeal penetration of saliva are common features in PD patients with daily drooling. The presence of hypoesthesia of the laryngeal structures and the lack of protective reflexes in such patients may play a major role in the mechanisms of SLP/SA.

Is silent aspiration a risk factor for respiratory infection in Parkinson's disease patients?

OBJECTIVE To assess if silent aspiration is a risk factor for respiratory infection in patients with Parkinsons disease (PD). METHOD From February 2006 to June 2006, 19 PD patients with diurnal sialorrhea were evaluated by swallow videofluoroscopy (VF). Two patients moved away and contact with them was lost. The other patients were divided into two groups according to the presence or absence of penetration/aspiration and were followed up for 1 year. During this period, patients were assessed for airway infections, hospital admissions, weight loss, use of nasoenteral or gastric tube and to detect cases of death. RESULTS Silent laryngeal penetration or silent aspiration (SLP/SA) was observed in four patients. During the follow up period, three of the four patients with SLP/SA developed respiratory infection, and one of the 13 patients who did not show SLP/SA had airway infection (RR=9.75, 95% CI: 1.36-69.65). Two patients with SLP/SA developed airway infection and died, and there were two deaths in the group who had not been diagnosed for SLP/SA, one due to cardiac arrest and the other related to pancreatic cancer. CONCLUSION The results suggest that patients with Parkinsons disease with diurnal sialorrhea and SLP/SA have an increased risk of respiratory infections, which is the main cause of death in PD patients. The data support a greater emphasis on preventive interventions for silent aspirations and silent penetration to improve survival in patients with Parkinsons disease.

BOTULINUM TOXIN TYPE A FOR THE TREATMENT OF THE UPPER LIMB SPASTICITY AFTER STROKE A meta-analysis

Muscle over-activity is one of the cardinal features of spasticity and it is a common disability of stroke patients. In this group, spasticity is responsible for several limitations that interfere in their daily activities and quality of life. To treat spasticity, neurologists usually prescribe drugs as baclofen, tizanidine or benzodiazepines or even use definitive treatment as phenol or surgery. Authors suggest the use of botulinum toxin type A (BTX-A) for spasticity in the upper limbs after stroke, but there are few papers with adequate methodology supporting this idea. In this article we summarize the data of previous double-blind, randomised clinical trials to asses, with a meta-analysis, if BTX-A is an adequate treatment for spasticity due to stroke. The results show a statistical superiority of BTX-A ov%r placebo on reducing muscle tone by the Modified Ashworth Scale (WMD= 0.95 [0.74 to 1.17]) in patients with post-stroke upper limb spasticity.

17p duplicated Charcot-Marie-Tooth 1A: characteristics of a new population.

AbstractThe most frequent type of Charcot–Marie–Tooth (CMT) neuropathy is that associated with the 17p11.2–p12 chromosome duplication, whose characteristics have been well described in European and North American populations. In this study, we analyzed a Brazilian population exhibiting the mutation, found in 57 patients from 42 families (79%) of a cohort of 53 families with demyelinating CMT. Almost 20% of the duplicated cases were sporadic. In 77% of the duplicated families the mutation event occurred in the hot spot area of the CMT1A–Rep region. Forty–five percent of patients were females, 84% were Caucasians and 13% of African descent. Distal limb weakness was the most frequent abnormality, appearing in 84% of patients, although uncommon manifestations such as severe proximal weakness, floppy baby syndrome, diaphragmatic weakness and severe scoliosis were also observed. One patient was wheelchair–bound, and three suffered severe hand weakness. Sensory abnormalities were detected in 84% of the cases, but 80% were unaware of this impairment. Twelve patients complained of positive sensory manifestations such as pain and paresthesias. Progression was reported by 40%. Motor conduction velocities in the upper limbs were always less than 35 m/s, and less than 30.4 m/s in the peroneal nerve. The findings of this study expand the clinical spectrum of the disease.

Does botulinum toxin improve the function of the patient with spasticity after stroke

Post-stroke spasticity is an important cause of disability in adults, due to muscle hyperactivity, which results in limb stiffness and muscle spasm. The prognosis for these patients depends on several features such as early management and adequate physical therapy to avoid muscle shortening, pain, and their consequences. Although several papers have shown that intramuscular injections of botulinum toxin type A (BT-A) decreases spasticity in post-stroke patients, few authors have demonstrated functional improvement after this therapy. In order to assess if individualized BT-A injections improves upper limb function in post-stroke spastic patients, we prospectively followed 20 consecutive patients of 18 years of age or more with spastic hemiparesis secondary to stroke. Fulg-Meyer scale modified for upper limbs, measure of functional independence (MFI), Ashworth modified scale, and goniometry were applied in the beginning of the investigation and in the 16th and 32nd weeks. BT-A was applied at baseline and in the 16th week. All subjects were submitted to rehabilitation therapy. All patients showed improvement according to Ashworth modified scale and increase in the range of motion, which were sustained until the 32nd week (p<0.05). The assessment of the first three parameters of the Fulg-Meyer scale and the evaluations of the motor part of the Functional Independence Measure showed statistically improvement until the end of the study. We conclude that proper choice of muscles and individualized doses of BT-A can improve function in selected post-stroke patients.Espasticidade secundaria a acidente vascular cerebral (AVC) e importante causa de incapacidade em adultos. O prognostico para estes pacientes depende de varios fatores como tratamento precoce e terapia fisica adequada, evitando encurtamento muscular, dor e outras consequencias. Varios estudos tem demonstrado que aplicacoes intramusculares de toxina botulinica do tipo A (TxB-A) reduzem a espasticidade apos AVC, entretanto poucos autores observaram melhora funcional de membros superiores com esta terapeutica. Para determinar se aplicacoes individualizadas de TxB-A melhoram a funcao no membro superior espastico de pacientes com hemiparesia secundaria a AVC, acompanhamos 20 pacientes com historia de AVC entre 6 meses e 5 anos. A escala de Fulg-Meyer para membros superiores, a medida de independencia funcional, a escala modificada de Ashworth e goniometria foram aplicadas no inicio da investigacao, na 16a e 32a semanas. TxB-A foi aplicada no inicio do estudo e na 16a semana e todos os participantes foram tratados adicionalmente com fisioterapia. Observamos melhora na escala de Ashworth e aumento na amplitude de movimento em todos os pacientes ate a 32a semana (p<0.05). A analise dos 3 primeiros parâmetros da escala de Fulg-Meyer e a parte motora da MIF mostraram melhora estatisticamente significante ate o final do estudo. Concluimos que a escolha adequada dos musculos e doses individualizadas de TxB-A melhoram a funcao em pacientes com espasticidade pos-AVC

Swallowing impairment and pulmonary dysfunction in Parkinson's disease: The silent threats

INTRODUCTION Swallowing disorders and respiratory impairment are frequent in Parkinsons disease (PD) patients, and aspiration pneumonia remains the leading cause of death among these subjects. OBJECTIVE The objective of this study was to investigate whether there is an association between pulmonary impairment and swallowing dysfunction in PD patients. METHODS A cross-sectional study with a comparison group was conducted with PD patients. Subjects were submitted to demographic questionnaires and underwent spirometric and videofluorographic assessments. Significance level was considered at 95% (p<0.05). RESULTS Among 35 PD patients, 40% presented with swallowing complaints. However, 22% of the clinically asymptomatic patients presented airway food penetration when submitted to videofluoroscopy. In 20% of PD patients material entered the airways and there was contact with the vocal folds in 7%. However, there was an efficient cleaning with residue deglutition in almost all patients. No penetration/aspiration was detected among the controls. Respiratory parameters were below the normal predicted values in PD patients when compared to the healthy controls. CONCLUSION These data suggest an association between pulmonary dysfunction and swallowing impairment in PD patients; even in patients without swallowing complaints, impaired pulmonary function can be detected.